ScripSellas Life Sciences Group’s tambiciclib (SLS009) is getting closer to pivotal development in what may be the first of multiple oncology indications as the company announced positive results from its
In VivoIn the top alliance by deal value, BioNTech and Bristol Myers Squibb entered into a potential $11.1bn agreement for the global co-development and co-commercialization of BioNTech’s bispecific antibody
In VivoRegardless of the political turmoil at home and abroad this year, global biopharma companies’ and investors’ interest in South Korea appears to be intact or even growing, amid continued solid R&D
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. JCR Adds $825m Gene Therapy Tech D